NexGel Q2 FY26 gross profit falls 11.84% to $1.11 million; revenue rises 27.8% to $3.69 million

• NexGel posted Q2 revenue of $3.69 million, up 27.8% year over year, driven by $814,000 of new Biomaterial product sales.
• Gross profit fell to $1.11 million from a year earlier; gross margin dropped 13.5 percentage points to 30.1%.
• Selling, general and administrative expenses jumped to $3.59 million, up 89.8%, on BioNX Surgical buildout costs and Celularity license amortization.
• For the first half, revenue rose 11.4% to $6.34 million, while gross margin slid 8.8 percentage points to 34.2%.
• Cash and cash equivalents ended June 30 at $1.71 million; working capital swung to negative $8.27 million from $1.38 million at year-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexgel Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-038555), on August 17, 2026, and is solely responsible for the information contained therein.